NASDAQ · CSBR
Healthcare · Biotechnology
$4.83
Up+$0.02 (+0.42%)
Updated Nov 5, 2026, 3:42 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CSBR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
CSBR closed at $4.83 after 21 trading sessions, down 1.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $4.9227 | $4.94 | $4.83 | $4.83 | 3.03K |
| Nov 3, 2026 | $4.91 | $5.06 | $4.81 | $4.83 | 7.36K |
| Nov 2, 2026 | $4.98 | $5.03 | $4.77 | $4.81 | 12.96K |
| Oct 30, 2026 | $4.8557 | $4.95 | $4.76 | $4.81 | 8.44K |
| Oct 29, 2026 | $5.075 | $5.075 | $4.80 | $4.81 | 15.35K |
| Oct 28, 2026 | $4.86 | $5.0914 | $4.83 | $4.92 | 10.93K |
| Oct 27, 2026 | $4.853 | $4.94 | $4.81 | $4.83 | 3.4K |
| Oct 26, 2026 | $4.80 | $5.025 | $4.80 | $4.86 | 15.13K |
| Oct 23, 2026 | $4.6527 | $4.78 | $4.6369 | $4.72 | 3.68K |
| Oct 22, 2026 | $4.93 | $5.05 | $4.69 | $4.76 | 16K |
| Oct 21, 2026 | $5.15 | $5.15 | $4.85 | $4.85 | 2.42K |
| Oct 20, 2026 | $4.6901 | $4.82 | $4.6901 | $4.81 | 1.77K |
| Oct 19, 2026 | $4.79 | $4.79 | $4.63 | $4.69 | 14.92K |
| Oct 16, 2026 | $4.835 | $4.835 | $4.70 | $4.70 | 1.84K |
| Oct 15, 2026 | $4.7999 | $4.855 | $4.7488 | $4.79 | 9.91K |
| Oct 14, 2026 | $4.76 | $4.865 | $4.76 | $4.81 | 2.96K |
| Oct 13, 2026 | $4.81 | $4.93 | $4.72 | $4.90 | 3.07K |
| Oct 12, 2026 | $4.84 | $4.9533 | $4.82 | $4.9533 | 11.4K |
| Oct 9, 2026 | $4.91 | $4.99 | $4.84 | $4.84 | 1.87K |
| Oct 8, 2026 | $4.875 | $5.00 | $4.875 | $4.98 | 2.83K |
| Oct 7, 2026 | $4.93 | $5.00 | $4.80 | $4.88 | 27.22K |
The latest Smart Investors Daily articles mentioning CSBR.
Company
Market Activity
Research & News
CSBR research
Company profile and research snapshot.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 12, 2025 | Craig-Hallum | Buy | — |
| Dec 12, 2024 | Craig-Hallum | Buy | — |
| Sep 12, 2024 | Craig-Hallum | Buy | — |
| Mar 13, 2024 | Craig-Hallum | Hold | — |
| Sep 22, 2023 | Roth MKM | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 8, 2026
On Monday, Champions Oncology (NASDAQ:CSBR) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Benzinga · Oct 8, 2026
Champions Oncology (NASDAQ:CSBR) released third-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
Benzinga · Oct 8, 2026
On Thursday, Champions Oncology (NASDAQ:CSBR) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Yahoo · Sep 22, 2026
PDX adoption is rising as pharma seeks predictive oncology models for precision medicine, biomarker discovery and drug screening, supported by sequencing advances and research partnerships.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Patient Derived Xenograft / PDX Models - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Patient Derived Xenograft / PDX Models was valued at US$467.5 Million in 2024 and is projected to reach US$1 Billion b
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CSBR.
